Skip to main content
RYM
NASDAQ Industrial Applications And Services

RYTHM Q2 Revenue Surges to $23M on Fixed Licensing Deal; $80M Debt Maturity Looms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Engineering & Construction Stocks · Industrial
Sentiment info
Neutral
Importance info
8
Price
$20.65
Mkt Cap
$44.999M
52W Low
$14
52W High
$53.65
52W Position info
47% above low
Off High info
62% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

RYM sits 47% above its 52-week low of $14 on elevated volume (1.9× avg).

Summary

RYTHM posted Q2 revenue of $23 million and net income of $1.2 million, but faces $80 million in debt maturities and a looming federal ban on its hemp-derived THC products.


Key Events · Earnings and Guidance · RYM

  • Q2 Revenue Hits $23M

    Revenue surged 73% sequentially to $23.0 million, driven by $17.5 million in licensing fees from a fixed annual agreement with Green Thumb and $5.5 million in product sales.

  • Net Income Turns Positive

    Net income was $1.2 million, or $0.09 per share, compared to a $7.4 million loss a year ago, boosted by a $1.2 million tax benefit from releasing valuation allowances.

  • $80M Debt Maturity Looms

    Convertible notes totaling $80 million mature by February 2027, with $72 million held by related party Green Thumb. Management expects to extend or convert the notes, but cash repayment would strain liquidity.

  • Federal Ban Threatens Core Products

    Legislation effective November 12, 2026 would cap THC content at 0.4 mg per container, potentially forcing reformulation or discontinuation of RYTHM's hemp-derived beverages and edibles.


Analysis · RYM · Industrial Applications And Services

A new $70 million annual fixed licensing agreement with Green Thumb propelled RYTHM's Q2 revenue to $23 million, swinging the bottom line to a net profit of $1.2 million. The turnaround was further aided by a $26.8 million non-cash tax benefit from releasing its valuation allowance. Yet significant challenges remain: $80 million in convertible notes mature by February 2027, with $72 million held by a related party, creating refinancing risk. Adding to the pressure, a pending federal ban on hemp-derived THC products effective November 2026 threatens the core product line, and a shareholder vote on August 10 could unlock massive dilution if Green Thumb converts its notes and warrants.

At the time of this filing, RYM was trading at $20.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $45M. The 52-week trading range was $14.00 to $53.65. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RYM - Latest Insights

RYM
Aug 04, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.65
Real-time Price: $20.65 info
Change: $0 (0%) info
Market Cap: $44.999M info
RYM
Jul 09, 2026, 9:13 AM EDT
Filing Type: DEF 14A
Importance Score:
10
Price at Filing: $22.61
Real-time Price: $20.65 info
Change: -$1.96 (-9%) info
Market Cap: $44.999M info
RYM
Jun 29, 2026, 7:00 AM EDT
Filing Type: PRE 14A
Importance Score:
10
Price at Filing: $28.37
Real-time Price: $20.65 info
Change: -$7.72 (-27%) info
Market Cap: $44.999M info
RYM
Jun 18, 2026, 4:21 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $27.98
Real-time Price: $20.65 info
Change: -$7.33 (-26%) info
Market Cap: $44.999M info
RYM
Jun 18, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.15
Real-time Price: $20.65 info
Change: -$6.50 (-24%) info
Market Cap: $44.999M info